Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1975 Apr;37(4):426–437. doi: 10.1136/hrt.37.4.426

Effects of the quaternary ammonium compound OX-572 on ventricular tachyarrhythmias complicating acute myocardial infarction.

L Rydén, A Hjalmarson, A Waldenström
PMCID: PMC483894  PMID: 1125119

Abstract

Patients with acute myocardial infarction who developed defined ventricular tachyarrhythmias were randomly allocated to two groups. The patients (n=34) in one of the groups received the quaternary ammonium compound N,N-bis (phenylcarbamoylmethyl) dimethylammoniumchloride (QX-572) intravenously as an infusion of 8 mg/kg body weight over 30 minutes. The patients in the other group (n=33) received saline and acted as controls. The analysis of arrhythmias was based on a continuous electrocardiogram recorded in parallel to routine monitoring during the 24 hours after the start of infusion. Only the detection of ventricular tachycardia or the development of ventricular fibrillation on routine monitoring could induce a change in antiarrhythmic treatment. The incidence of patients with ventricular tachycardia recorded was significantly lower in the QX-572 group (38%) than in the control group (73%). About half the number of patients with ventricular tachycardia recorded on the continuous electrocardiogram were also detected by means of routine monitoring. The number of patients with various types of ventricular premature contractions (1-5/min, greater than 5/min, paired, multifocal, R on T), ventricular tachycardia, and rapid idioventricular rhythm were compared within successive one-hour periods. For all types of ventricular tachyarrhythmias except rapid idioventricular rhythm there was a lower incidence of arrhythmias in the QX-572 group...

Full text

PDF
426

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bruyneel K. J., Opie L. H. The value of warning arrhythmias in the prediction of ventricular fibrillation within one hour of coronary occlusion. Experimental studies in the baboon. Am Heart J. 1973 Sep;86(3):373–384. doi: 10.1016/0002-8703(73)90047-1. [DOI] [PubMed] [Google Scholar]
  2. Dhurandhar R. W., MacMillan R. L., Brown K. W. Primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol. 1971 Apr;27(4):347–351. doi: 10.1016/0002-9149(71)90429-2. [DOI] [PubMed] [Google Scholar]
  3. Gillis R. A., Levine F. H., Thibodeaux H., Raines A., Standaert F. G. Comparison of methyllidocaine and lidocaine on arrhythmias produced by coronary occlusion in the dog. Circulation. 1973 Apr;47(4):697–703. doi: 10.1161/01.cir.47.4.697. [DOI] [PubMed] [Google Scholar]
  4. Harrison D. C., Alderman E. L. The pharmacology and clinical use of lidocaine as an antiarrhythmic drug--1972. Mod Treat. 1972 Feb;9(1):139–175. [PubMed] [Google Scholar]
  5. Henning R., Holmberg S. Erfarenheter från sahlgrenska sjuhusets hjärtinfarktavdelning. Lakartidningen. 1971 Aug 4;68(32):3603–3610. [PubMed] [Google Scholar]
  6. Holmberg S., Serzysko W., Varnauskas E. Coronary circulation during heavy exercise in control subjects and patients with coronary heart disease. Acta Med Scand. 1971 Dec;190(6):465–480. doi: 10.1111/j.0954-6820.1971.tb07462.x. [DOI] [PubMed] [Google Scholar]
  7. KATZ R. L. ANTIARRHYTHMIC ACTION OF N, N-BIS (PHENYLCARBAMOYLMETHYL) DIMETHYL AMMONIUM CHLORIDE (QX-572) IN CAT AND DOG. Anesthesiology. 1964 May-Jun;25:291–296. doi: 10.1097/00000542-196405000-00005. [DOI] [PubMed] [Google Scholar]
  8. Kniffen F. J., Lomas T. E., Nobel-Allen N. L., Lucchesi B. R. The comparative antiarrhythmic actions of lidocaine and its quarternary derivative, methyl lidocaine. Circulation. 1974 Feb;49(2):264–271. doi: 10.1161/01.cir.49.2.264. [DOI] [PubMed] [Google Scholar]
  9. Lown B., Vasaux C., Hood W. B., Jr, Fakhro A. M., Kaplinsky E., Roberge G. Unresolved problems in coronary care. Am J Cardiol. 1967 Oct;20(4):494–508. doi: 10.1016/0002-9149(67)90027-6. [DOI] [PubMed] [Google Scholar]
  10. NATHANS D., von EHRENSTEIN, MONRO R., LIPMANN F. Protein synthesis from aminoacyl-soluble ribonucleic acid. Fed Proc. 1962 Jan-Feb;21:127–133. [PubMed] [Google Scholar]
  11. Norris R. M., Mercer C. J., Yeates S. E. Idioventricular rhythm complicating acute myocardial infarction. Br Heart J. 1970 Sep;32(5):617–621. doi: 10.1136/hrt.32.5.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Robinson B. F. Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. Circulation. 1967 Jun;35(6):1073–1083. doi: 10.1161/01.cir.35.6.1073. [DOI] [PubMed] [Google Scholar]
  13. Romhilt D. W., Bloomfield S. S., Chou T. C., Fowler N. O. Unreliability of conventional electrocardiographic monitoring for arrhythmia detection in coronary care units. Am J Cardiol. 1973 Apr;31(4):457–461. doi: 10.1016/0002-9149(73)90294-4. [DOI] [PubMed] [Google Scholar]
  14. Rydén L., Hjalmarson A, Kvasnicka J., Liander B. Haemodynamic effects of the antiarrhythmic quaternary ammonium compound QX-572 in man. Br Heart J. 1975 Jan;37(1):65–73. doi: 10.1136/hrt.37.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rydén L., Olsson B., Kvasnicka J. Electrophysiological effects of the antiarrhythmic agent QX-572 in the human heart with special reference to rate-induced changes in effective refractory periods. Cardiovasc Res. 1975 Jan;9(1):81–94. doi: 10.1093/cvr/9.1.81. [DOI] [PubMed] [Google Scholar]
  16. SOWTON E., LEATHAM A., CARSON P. THE SUPPRESSION OF ARRHYTHMIAS BY ARTIFICIAL PACEMAKING. Lancet. 1964 Nov 21;2(7369):1098–1100. doi: 10.1016/s0140-6736(64)92615-7. [DOI] [PubMed] [Google Scholar]
  17. Schwartz M. L., Stapleton J., Covino B. G. Clinical pharmacology of N,N-bis(phenylcarbamolymethyl)dimethylammonium chloride (QX-572), a new antiarrhythmic agent. J Clin Pharmacol J New Drugs. 1967 Sep-Oct;7(5):278–286. doi: 10.1002/j.1552-4604.1967.tb00065.x. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES